Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Suzuki Y et al. - Entecavir in the long term would be useful for histological improvement of breakthrough hepatitis induced by lamivudine-resistant HBV mutants in patients with chronic hepatitis B. However, the relatively high rate of entecavir resistance is a concern, and other strategies need to be considered when available.

Related Articles

Entecavir for the long-term treatment of chronic hepatitis B
Expert Review of Anti-infective Therapy, 11/09/09    Relevance Score: 67%

Monotherapy versus combination therapy for the treatment of chronic hepatitis B
Expert Opinion on Investigational Drugs, 10/26/09    Relevance Score: 64%

Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B
Journal of Viral Hepatitis, 10/13/09    Relevance Score: 64%

Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain
AIDS Research and Human Retroviruses, 10/23/09    Relevance Score: 46%

Plasmid-Mediated Quinolone Resistance: a Multifaceted Threat
Clinical Microbiology Reviews, 10/14/09    Relevance Score: 46%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address